Evaluation of exenatide versus insulin glargine for the impact on endothelial functions and cardiovascular risk markers

Diabetes Research and Clinical Practice

Volumn 106, Issue 3, 2014, Pages 567-575

  Gurkan, Eren ^a   Tarkun, Ilhan ^a   Sahin, Tayfun ^a   Cetinarslan, Berrin ^a   Canturk, Zeynep ^a  

^a KOCAELI UNIVERSITY   (Turkey)

Author keywords

Cardiovascular disease; Exenatide; Insulin analogues; Type 2 diabetes

Indexed keywords

ADIPONECTIN; C REACTIVE PROTEIN; ENDOTHELIN 1; EXENDIN 4; FIBRINOGEN; INSULIN GLARGINE; INTERLEUKIN 6; LEPTIN; METFORMIN; MONOCYTE CHEMOTACTIC PROTEIN 1; PLASMINOGEN ACTIVATOR INHIBITOR 1; TUMOR NECROSIS FACTOR ALPHA; ANTIDIABETIC AGENT; BIOLOGICAL MARKER; GLUCAGON LIKE PEPTIDE 1; GLUCOSE BLOOD LEVEL; GLYCOSYLATED HEMOGLOBIN; LONG ACTING INSULIN; PEPTIDE; VENOM;

ADULT; AGED; ARTICLE; BEDTIME DOSAGE; BODY FAT; BODY MASS; CARDIOVASCULAR RISK; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG DOSE INCREASE; DRUG EFFICACY; ECHOGRAPHY; ENDOTHELIUM; ENZYME LINKED IMMUNOSORBENT ASSAY; FAT MASS; FEMALE; FOLLOW UP; HUMAN; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; OPEN STUDY; PARALLEL DESIGN; RANDOMIZED CONTROLLED TRIAL; VASODILATATION; BLOOD; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; COMPLICATION; DIABETES MELLITUS, TYPE 2; DRUG EFFECTS; GLUCOSE BLOOD LEVEL; METABOLISM; MIDDLE AGED; PATHOPHYSIOLOGY; PROGNOSIS; RISK FACTOR; VASCULAR ENDOTHELIUM;

BIOMARKERS; BLOOD GLUCOSE; BRACHIAL ARTERY; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; ENDOTHELIN-1; ENDOTHELIUM, VASCULAR; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; FOLLOW-UP STUDIES; GLUCAGON-LIKE PEPTIDE 1; HEMOGLOBIN A, GLYCOSYLATED; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN GLARGINE; INSULIN, LONG-ACTING; MALE; MIDDLE AGED; PEPTIDES; PROGNOSIS; RISK FACTORS; VASODILATION; VENOMS;

EID: 84920694437     PISSN: 01688227     EISSN: 18728227     Source Type: Journal    
DOI: 10.1016/j.diabres.2014.09.046     Document Type: Article

References (40)

1. Després J.P., Lemieux I., Bergeron J., Pibarot P., Mathieu P., Larose E., et al. Abdominal obesity and the metabolic syndrome: contribution to global cardiometabolic risk. Arterioscler Thromb Vasc Biol 2008, 28:1039-1049.
2. Frayn K.N. Adipose tissue and the insulin resistance syndrome. Proc Nutr Soc 2001, 60:375-380.
3. Hill M.J., Metcalfe D., McTernan P.G. Obesity and diabetes: lipids, 'nowhere to run to'. Clin Sci (Lond) 2009, 116:113-123.
4. Grau A.J., Buggle F., Becher H., Werle E., Hacke W. The association of leukocyte count, fibrinogen and C-reactive protein with vascular risk factors and ischemic vascular diseases. Thromb Res 1996, 82:245-255.
5. Ross R. Atherosclerosis-an inflammatory disease. N Engl J Med 1999, 340:115-126.
6. Ross R. The pathogenesis of atherosclerosis: a perspective for the 1990. Nature 1993, 362:801-809.
7. Deanfield J.E., Halcox J.P., Rabelink T.J. Endothelial function and dysfunction: testing and clinical relevance. Circulation 2007, 115:1285-1295.
8. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor-dependent and -independent pathways. Circulation 2008, 117:2340-2350.
9. Basu A., Charkoudian N., Schrage W.A., Rizza R.A., Basu R., Joyner M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295.
10. Corretti M.C., Anderson T.J., Benjamin E.J., Celermajer D., Charbonneau F., Creager M.A., et al. International Brachial Artery Reactivity Task Force, guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002, 39:257-265.
11. DeFronzo R.A., Ratner R.E., Han J., Kim D.D., Fineman M.S., Baron A.D. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care 2005, 28:1092-1100.
12. Heine R.J., Van Gaal L.F., Johns D., Mihm M.J., Widel M.H., Brodows R.G. Exenatide versus insulin glargine in patients with suboptimally controlled type 2 diabetes: a randomized trial. Ann Intern Med 2005, 143:559-569. GWAA Sttudy Group.
13. Bunck M.C., Diamant M., Cornér A., Eliasson B., Malloy J.L., Shaginian R.M., et al. One-year treatment with exenatide improves beta-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients: a randomized, controlled trial. Diabetes Care 2009, 32:762-768.
14. Ridker P.M., Buring J.E., Cook N.R., Rifai N. C-reactive protein, the metabolic syndrome, and risk of incident cardiovascular events: an 8-year follow-up of 14,719 initially healthy American women. Circulation 2003, 107:391-397.
15. Szayna M., Doyle M.E., Betkey J.A., Holloway H.W., Spencer R.G., Greig N.H., et al. Exendin-4 decelerates food intake, weight gain, and fat deposition in Zucker rats. Endocrinology 2000, 141:1936-1941.
16. Horton E.S., Cohen A., Gibson H., Lamparello B., Herzlinger S., McFarland L. Effects of exenatide vs insulin glargine on cardiovascular risk factors in subjects with type 2 diabetes. Diabetologia 2009, 52:S298-S299.
17. Plutzky J., Garber A.J., Falahati A., Toft A.D., Poulter N.R. The once daily human GLP-1-analogue, liraglutide, significantly reduces markers of cardiovascular risk in type 2 diabetes: a meta-analysis of six clinical trials, Eur. Heart J 2009, 30(Suppl 1):917-919.
18. Considine R.V., Sinha M.K., Heiman M.L., Kriauciunas A., Stephens T.W., Nyce M.R., et al. Serum immunoreactive-leptin concentrations in normal-weight and obese humans. N Engl J Med 1996, 334:292-295.
19. Ryan A.S., Elahi D. The effects of acute hyperglycemia and hyperinsulinemia on plasma leptin levels: its relationships with body fat, visceral adiposity, and age in women. J Clin Endocrinol Metab 1996, 81:4433-4438.
20. Bunck M.C., Diamant M., Eliasson B., Cornér A., Shaginian R.M., Heine R.J., et al. Exenatide affects circulating cardiovascular risk biomarkers independently of changes in body composition. Diabetes Care 2010, 33:1734-1737.
21. Chaudhuri A., Ghanim H., Vora M., Sia C.L., Korzeniewski K., Dhindsa S., et al. Exenatide exerts a potent antiinflammatory effect. J Clin Endocrin Metab 2012, 97:198-207.
22. Li L., Yang G., Li Q., Tan X., Liu H., Tang Y., et al. Exenatide prevents fat-induced insulin resistance and raises adiponectin expression and plasma levels. Diabetes Obes Metab 2008, 10:921-930.
23. Potenza M.A., Marasciulo F.L., Chieppa D.M., Brigiani G.S., Formoso G., Quon M.J., et al. Insulin resistance in spontaneously hypertensive rats is associated with endothelial dysfunction characterized by imbalance between NO and ET-1 production. Am J Physiol Heart Circ Physiol 2005, 289:H813-H822.
24. Cardillo C., Campia U., Bryant M.B., Panza J.A. Increased activity of endogenous endothelin in patients with type II diabetes mellitus. Circulation 2002, 106:1783-1787.
25. Shemyakin A., Salehzadeh F., Esteves Duque-Guimaraes D. Endothelin-1 reduces glucose uptake in human skeletal muscle in vivo and in vitro. Diabetes 2011, 60:2061-2067.
26. Shemyakin A., Böhm F., Wagner H.A., Efendic S., Båvenholm P., Pernow J. Enhanced endothelium-dependent vasodilatation by dual endothelin receptor blockade in individuals with insulin resistance. J Cardiovasc Pharmacol 2006, 47:385-390.
27. Sartipy P., Loskutoff D.J. Monocyte chemoattractant protein 1 in obesity and insulin resistance. Proc Natl Acad Sci USA 2003, 100:7265-7270.
28. Nomura S., Shouzu A., Omoto S., Nishikawa M., Fukuhara S. Significance of chemokines and activated platelets in patients with diabetes. Clin Exp Immunol 2000, 121:437-443.
29. Wu J.D., Xu X.H., Zhu J., Ding B., Du T.X., Gao G., et al. Effect of exenatide on inflammatory and oxidative stress markers in patients with type 2 diabetes mellitus. Diabetes Technol Ther 2011, 13:143-148.
30. Courrèges J.P., Vilsbøll T., Zdravkovic M., Le-Thi T., Krarup T., Schmitz O., et al. Beneficial effects of once-daily liraglutide, a human glucagon-like peptide-1 analogue, on cardiovascular risk biomarkers in patients with type 2 diabetes. Diabet Med 2008, 25:1129-1131.
31. Bergenstal R.M., Wysham C., Macconell L., Malloy J., Walsh B., Yan P., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomized trial. The Lancet 2010, 376:431-439.
32. Forst T., Hohberg C., Pfutzner A. Cardiovascular effects of disturbed insulin activity in metabolic syndrome and in type 2 diabetic patients. Horm Metab Res 2009, 41:123-131.
33. Van den Oever I.A., Raterman H.G., Nurmohamed M.T., Simsek S. Endothelial dysfunction, inflammation and apoptosis in diabetes mellitus. Mediators Inflamm 2010, 2010:792393.
34. Vehkavaara S., Yki-Järvinen H. 3.5 years of insulin therapy with insulin glargine improves in vivo endothelial function in type 2 diabetes. Arterioscler Thromb Vasc Biol 2004, 24:325-330.
35. Ban K., Noyan-Ashraf M.H., Hoefer J., Bolz S.S., Drucker D.J., Husain M. Cardioprotective and vasodilatory actions of glucagon-like peptide 1 receptor are mediated through both glucagon-like peptide 1 receptor dependent and independent pathways. Circulation 2008, 117:2340-2350.
36. Nyström T., Gutniak M.K., Zhang Q., Zhang F., Holst J.J., Ahrén B., et al. Effects of glucagon-like peptide-1 on endothelial function in type 2 diabetes patients with stable coronary artery disease. Am J Physiol Endocrinol Metab 2004, 287:E1209-E1215.
37. Hattori Y., Jojima T., Tomizawa A., Satoh H., Hattori S., Kasai K., et al. A glucagon-like peptide-1 (GLP-1) analogue, liraglutide, upregulates nitric oxide production and exerts anti-inflammatory action in endothelial cells. Diabetologia 2010, 53:2256-2263.
38. Liu H., Hu Y., Simpson R.W., Dear A.E. Glucagon-like peptide-1 attenuates tumor necrosis factor-α-mediated induction of plasmogen activator inhibitor-1 expression. J Endocrinol 2008, 196:57-65.
39. Basu A., Charkoudian N., Schrage W., Rizza R.A., Basu R., Joyner M.J. Beneficial effects of GLP-1 on endothelial function in humans: dampening by glyburide but not by glimepiride. Am J Physiol Endocrinol Metab 2007, 293:E1289-E1295.
40. Irace C., De Luca S., Shehaj E., Carallo C., Loprete A., Scavelli F., et al. Exenatide improves endothelial function assessed by flow mediated dilation technique in subjects with type 2 diabetes: results from an observational research. Diab Vasc Dis Res 2013, 10:72-77.